In this episode of Treating Together, host Marc Braunstein, MD, an associate professor of medicine at the Perlmutter Cancer Center, NYU Grossman School of Medicine, is joined by John Burke, MD, from Rocky Mountain Cancer Centers. Both specialists bring their extensive experience in lymphoma and multiple myeloma to a deep-dive discussion on the rapidly evolving treatment landscape of chronic lymphocytic leukemia (CLL).

Key Discussion Points
The episode focuses on the refinement of CLL therapy, moving away from traditional chemoimmunotherapy toward targeted approaches. Highlights include:

Looking Toward the Future
As the experts look ahead into 2026, they discuss the promising emergence of BTK degraders, which have shown high response rates in heavily pretreated patients and are moving toward potential market availability in the coming years.